Homogenous preparations of il-28 and il-29
AssigneeZymoGenetics, Inc.
InventorsLowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Life of this patent
Estimating the term…
Abstract
Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Claims19
A method of treating a patient having a hepatitis C virus infection comprising administering to the patient a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:159, wherein in said amino acid sequence the amino acid residue that corresponds to position 166 of SEQ ID NO:159 is Ser, Ala, Thr, Val, or Asn, and wherein the polypeptide has anti-hepatitis C activity,
- and a pharmaceutically acceptable vehicle,
- wherein after administration of the composition the hepatitis C infection is reduced.
A method of treating a patient having a hepatitis C virus infection comprising administering to the patient a therapeutically effective amount of a composition comprising a fusion protein comprising a polypeptide that comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:159 and a polyalkyl oxide moiety, wherein in said amino acid sequence the amino acid residue that corresponds to position 166 of SEQ ID NO:159 is Ser, Ala, Thr, Val, or Asn, and wherein the polypeptide has anti-hepatitis C activity,
- and a pharmaceutically acceptable vehicle,
- wherein after administration of the composition the hepatitis C infection is reduced.
An isolated polypeptide comprising an amino acid sequence having at least 96% sequence identity to SEQ ID NO:159, wherein in said amino acid sequence the amino acid residue that corresponds to position 166 of SEQ ID NO:159 is Ser, Ala, Thr, Val, or Asn, and the amino acid residue that corresponds to position 1 of SEQ ID NO:159 is Met, and
- wherein the polypeptide has anti-hepatitis C activity.
Dependencies are inferred from the claim text.